|Mr. Mark J. Fitzpatrick||Pres, CEO & Director||770.3k||N/A||1963|
|Mr. Drew Enamait||VP of Fin. & Admin. and Principal Accounting Officer||315.1k||N/A||1974|
|Dr. William H. Ludlam||Sr. VP of Clinical Devel. & Medical Affairs||505.95k||N/A||1965|
|Dr. Gary Patou||Head of Clinical||N/A||N/A||1959|
Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.
Chiasma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.